<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35177833</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1474-1784</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Drug discovery</Title>
          <ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.</ArticleTitle>
        <Pagination>
          <StartPage>306</StartPage>
          <EndPage>318</EndPage>
          <MedlinePgn>306-318</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-022-00391-w</ELocationID>
        <Abstract>
          <AbstractText>Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal of amyloid plaque from brains of patients with AD, and the FDA has recently granted accelerated approval to one of these, aducanumab, using reduction of amyloid plaque as a surrogate end point. The rationale for approval and the extent of the clinical benefit from these antibodies are under intense debate. With the aim of informing this debate, we review clinical trial data for drugs that target Aβ from the perspective of the temporal interplay between the two pathognomonic protein aggregates in AD - Aβ plaques and tau neurofibrillary tangles - and their relationship to cognitive impairment, highlighting differences in drug properties that could affect their clinical performance. On this basis, we propose that Aβ pathology drives tau pathology, that amyloid plaque would need to be reduced to a low level (~20 centiloids) to reveal significant clinical benefit and that there will be a lag between the removal of amyloid and the potential to observe a clinical benefit. We conclude that the speed of amyloid removal from the brain by a potential therapy will be important in demonstrating clinical benefit in the context of a clinical trial.</AbstractText>
          <CopyrightInformation>© 2022. Springer Nature Limited.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Karran</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0002-6782-5213</Identifier>
            <AffiliationInfo>
              <Affiliation>Cambridge Research Center, AbbVie, Inc., Cambridge, MA, USA. eric.karran@abbvie.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Strooper</LastName>
            <ForeName>Bart</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0001-5455-5819</Identifier>
            <AffiliationInfo>
              <Affiliation>VIB Centre for Brain Disease Research, KU Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Drug Discov</MedlineTA>
        <NlmUniqueID>101124171</NlmUniqueID>
        <ISSNLinking>1474-1776</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35177833</ArticleId>
        <ArticleId IdType="doi">10.1038/s41573-022-00391-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41573-022-00391-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Karran, E., Mercken, M. &amp; De Strooper, B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698–712 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21852788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704–706 (1991).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1671712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375, 754–760 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7596406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogaev, E. I. et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376, 775–778 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7651536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22801501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8232972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knopman, D. S., Jones, D. T. &amp; Greicius, M. D. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dementia 17, 696–701 (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. Drug approval package: Aduhelm (aducanumab-avwa). Office of Neurology’s summary review memorandum. FDA https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000TOC.cfm (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, G. C. et al. Revisiting FDA approval of aducanumab. N. Engl. J. Med. 385, 769–771 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34320282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalton, R. M., Krishnan, H. S., Parker, V. S., Catanese, M. C. &amp; Hooker, J. M. Coevolution of atomic resolution and whole-brain imaging for tau neurofibrillary tangles. ACS Chem. Neurosci. 11, 2513–2522 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32786315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol. Psychiatry 24, 1112–1134 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30635637</ArticleId>
            <ArticleId IdType="pmc">6756230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villemagne, V. L., Dore, V., Burnham, S. C., Masters, C. L. &amp; Rowe, C. C. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 14, 225–236 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29449700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jagust, W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat. Rev. Neurosci. 19, 687–700 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30266970</ArticleId>
            <ArticleId IdType="pmc">7032048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thal, D. R., Rub, U., Orantes, M. &amp; Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12084879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grothe, M. J. et al. In vivo staging of regional amyloid deposition. Neurology 89, 2031–2038 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29046362</ArticleId>
            <ArticleId IdType="pmc">5711511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. &amp; Hansson, O. Staging beta-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. 76, 1319–1329 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31314895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25988462</ArticleId>
            <ArticleId IdType="pmc">4486209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak, H. &amp; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1759558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25348064</ArticleId>
            <ArticleId IdType="pmc">4257842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowe, V. J. et al. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology 93, e29–e39 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31147421</ArticleId>
            <ArticleId IdType="pmc">6659005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748–763 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28077397</ArticleId>
            <ArticleId IdType="pmc">5382945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Strooper, B. &amp; Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26871627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villemagne, V. L. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23477989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattsson-Carlgren, N. et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology 94, e2233–e2244 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32398359</ArticleId>
            <ArticleId IdType="pmc">7357296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain 142, 1723–1735 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31009046</ArticleId>
            <ArticleId IdType="pmc">6536847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knopman, D. S. et al. Association of initial beta-amyloid levels with subsequent flortaucipir positron emission tomography changes in persons without cognitive impairment. JAMA Neurol. 78, 217–228 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33074304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez, J. S. et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography. Sci. Transl. Med. 13, eabc0655 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33472953</ArticleId>
            <ArticleId IdType="pmc">7978042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong, W. et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble Abeta in Alzheimer’s disease brain. Acta Neuropathol. 136, 19–40 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29687257</ArticleId>
            <ArticleId IdType="pmc">6647843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh, D. M. &amp; Selkoe, D. J. Amyloid β-protein and beyond: the path forward in Alzheimer’s disease. Curr. Opin. Neurobiol. 61, 116–124 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32197217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benilova, I., Karran, E. &amp; De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349–357 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22286176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karran, E. &amp; Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76, 185–205 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24853080</ArticleId>
            <ArticleId IdType="pmc">4204160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 369, 341–350 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23883379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman, R. J. et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66, 48–54 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19360898</ArticleId>
            <ArticleId IdType="pmc">2730994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Strooper, B. Lessons from a failed gamma-secretase Alzheimer trial. Cell 159, 721–726 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25417150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bray, S. J. Notch signalling in context. Nat. Rev. Mol. Cell Biol. 17, 722–735 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Doody, R. S. et al. Peripheral and central effects of gamma-secretase inhibition by semagacestat in Alzheimer’s disease. Alzheimers Res. Ther. 7, 36 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26064192</ArticleId>
            <ArticleId IdType="pmc">4461930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egan, M. F. et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N. Engl. J. Med. 380, 1408–1420 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30970186</ArticleId>
            <ArticleId IdType="pmc">6776078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378, 1691–1703 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29719179</ArticleId>
            <ArticleId IdType="pmc">6776074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hampel, H. et al. The β-secretase BACE1 in Alzheimer’s disease. Biol. Psychiatry 89, 745–756 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32223911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Racke, M. M. et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629–636 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15659599</ArticleId>
            <ArticleId IdType="pmc">6725332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24450890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29365294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siemers, E. R. et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 12, 110–120 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26238576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman, R. J. et al. The DIAN-TU next generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8–19 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27583651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, G. et al. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer’s disease. Stat. Med. 37, 3047–3055 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29761523</ArticleId>
            <ArticleId IdType="pmc">6105413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. Nat. Med. 27, 1187–1196 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34155411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ultsch, M. et al. Structure of crenezumab complex with Abeta shows loss of beta-hairpin. Sci. Rep. 6, 39374 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27996029</ArticleId>
            <ArticleId IdType="pmc">5171940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farlow, M. et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 8, 261–271 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22672770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida, K. et al. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease. Alzheimers Res. Ther. 12, 16 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31969177</ArticleId>
            <ArticleId IdType="pmc">6977279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meilandt, W. J. et al. Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ. Alzheimers Res. Ther. 11, 97 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31787113</ArticleId>
            <ArticleId IdType="pmc">6886224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salloway, S. et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimers Res. Ther. 10, 96 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30231896</ArticleId>
            <ArticleId IdType="pmc">6146627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, T. et al. Target engagement in an alzheimer trial: crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Ann. Neurol. 86, 215–224 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31168802</ArticleId>
            <ArticleId IdType="pmc">6771589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brothers, H. M., Gosztyla, M. L. &amp; Robinson, S. R. The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer’s disease. Front. Aging Neurosci. 10, 118 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29922148</ArticleId>
            <ArticleId IdType="pmc">5996906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–919 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10932230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demattos, R. B. et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease mice. Neuron 76, 908–920 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23217740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367–385 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21784348</ArticleId>
            <ArticleId IdType="pmc">3693547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosen, W. G., Mohs, R. &amp; Davis, K. L. A new rating scale for Alzheimer’s disease. Am. J. Psychiatry 141, 1356–1364 (1984).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6496779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gélinas, I., Gauthier, L., Mcintyre, M. &amp; Gauthier, S. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am. J. Occup. Ther. 53, 471–481 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10500855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24450891</ArticleId>
            <ArticleId IdType="pmc">4159618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, E. et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692–700 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26208959</ArticleId>
            <ArticleId IdType="pmc">4553028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bohrmann, B. et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49–69 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21955818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198–207 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21987394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrowitzki, S. et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res. Ther. 9, 95 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29221491</ArticleId>
            <ArticleId IdType="pmc">5723032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsberth, C. et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat. Neurosci. 4, 887–893 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11528419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logovinsky, V. et al. Safety and tolerability of BAN2401–a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res. Ther. 8, 14 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27048170</ArticleId>
            <ArticleId IdType="pmc">4822297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satlin, A. et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimers Dement. 2, 1–12 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Wang, J. et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J. Neurol. Neurosurg. Psychiatry 87, 993–999 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27010616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian, J., Betensky, R. A., Hyman, B. T. &amp; Serrano-Pozo, A. Association of APOE genotype with heterogeneity of cognitive decline rate in Alzheimer disease. Neurology 96, e2414–e2428 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33771840</ArticleId>
            <ArticleId IdType="pmc">8166439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki, K. et al. Effect of apolipoprotein E epsilon4 allele on the progression of cognitive decline in the early stage of Alzheimer’s disease. Alzheimers Dement. 6, e12007 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res. Ther. 13, 80 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33865446</ArticleId>
            <ArticleId IdType="pmc">8053280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reyderman, L. et al. BAN2401 and ARIA-E in early Alzheimer’s disease: pharmacokinetic / pharmacodynamic time-to-event analysis from the phase 2 study in early Alzheimer’s disease. J. Prev. Alzheimer’s Dis. 7, S17 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Aisen, P. et al. AHEAD 3-45 study design: a global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimers Dement. 16 (Suppl. 9), e044511 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Lord, A. et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 36, 425–434 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19703562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arndt, J. W. et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci. Rep. 8, 6412 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29686315</ArticleId>
            <ArticleId IdType="pmc">5913127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sevigny, J. et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27582220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budd Haeberlein, S. et al. Evaluation of aducanumab efficacy in early Alzheimer’s disease. Presented at 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Saido, T. C. et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457–466 (1995).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7857653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo, Y.-M., Emmerling, M. R., Woods, A. S., Cotter, R. J. &amp; Roher, A. E. Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res. Commun. 237, 188–191 (1997).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9266855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowe, S. L. et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dementia 7, e12112 (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Lobo, E. D., Hansen, R. J. &amp; Balthasar, J. P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645–2668 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15389672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irizarry, M. C. et al. O4-08-06: safety, pharmacokinetics (PK), and florbetapir F-18 positron emission tomography (PET) after multiple dose administration of LY3002813, a β-amyloid plaque-specific antibody, in Alzheimer’s disease (AD). Alzheimers Dement. 12, P352 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Wessels, A. M. et al. A combined measure of cognition and function for clinical trials: the integrated Alzheimer’s disease rating scale (iADRS). J. Prev. Alzheimers Dis. 2, 227–241 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27019841</ArticleId>
            <ArticleId IdType="pmc">4806404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mintun, M. A. et al. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384, 1691–1704 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33720637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 11, 669–678 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22749065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Joie, R. et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 15, 205–216 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30347188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dore, V. et al. Comparison of (18)F-florbetaben quantification results using the standard centiloid, MR-based, and MR-less CapAIBL((R)) approaches: validation against histopathology. Alzheimers Dement. 15, 807–816 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31101517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amadoru, S. et al. Comparison of amyloid PET measured in centiloid units with neuropathological findings in Alzheimer’s disease. Alzheimers Res. Ther. 12, 22 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32131891</ArticleId>
            <ArticleId IdType="pmc">7057642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack, C. R. et al. Predicting future rates of tau accumulation on PET. Brain 143, 3136–3150 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33094327</ArticleId>
            <ArticleId IdType="pmc">7586089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein, G. et al. Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res. Ther. 11, 101 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31831056</ArticleId>
            <ArticleId IdType="pmc">6909550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boche, D., Denham, N., Holmes, C. &amp; Nicoll, J. A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer’s disease pathogenesis. Acta Neuropathol. 120, 369–384 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20632020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scherpelz, K. P. et al. Atomic-level differences between brain parenchymal- and cerebrovascular-seeded Abeta fibrils. Sci. Rep. 11, 247 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33420184</ArticleId>
            <ArticleId IdType="pmc">7794565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda, J. et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J. Neurosci. 27, 10957–10968 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17928437</ArticleId>
            <ArticleId IdType="pmc">6672864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi, M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer’s disease. Curr. Alzheimer Res. 6, 137–143 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19355848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322–e333 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31289148</ArticleId>
            <ArticleId IdType="pmc">6669933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961–970 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24886908</ArticleId>
            <ArticleId IdType="pmc">4439182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zetterberg, H. &amp; Blennow, K. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Mol. Neurodegener. 16, 10 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33608044</ArticleId>
            <ArticleId IdType="pmc">7893769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander, G. C., Emerson, S. &amp; Kesselheim, A. S. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325, 1717–1718 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33783469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander, G. C. &amp; Karlawish, J. The problem of aducanumab for the treatment of Alzheimer disease. Ann. Intern. Med. 174, 1303–1304 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34138642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings, J. et al. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res. Ther. 13, 98 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33971962</ArticleId>
            <ArticleId IdType="pmc">8111757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doody, R. Editorial: Consequences of the FDA decision on aducanumab for patient care and research. J. Prev. Alzheimers Dis. 8, 393–395 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34585210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn, B., Stein, P. &amp; Cavazzoni, P. Approval of aducanumab for Alzheimer disease-the FDA’s perspective. JAMA Intern. Med. 181, 1276–1278 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34254984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn, B., Stein, P., Temple, R. &amp; Cavazzoni, P. An appropriate use of accelerated approval- aducanumab for Alzheimer’s disease. N. Engl. J. Med. 385, 856–857 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34320283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen, R. C. Aducanumab: what about the patient? Ann. Neurol. 90, 334–335 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34322904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabinovici, G. D. Controversy and progress in Alzheimer’s disease - FDA approval of aducanumab. N. Engl. J. Med. 385, 771–774 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34320284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salloway, S. &amp; Cummings, J. Aducanumab, amyloid lowering, and slowing of Alzheimer disease. Neurology 97, 543–544 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34233942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinbrook, R. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern. Med. 181, 1281 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34254991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings, J. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheimers Dis. 8, 398–410 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34585212</ArticleId>
            <ArticleId IdType="pmc">8835345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939–1949 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25988463</ArticleId>
            <ArticleId IdType="pmc">4517678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niewoehner, J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49–60 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24411731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber, F. et al. Brain shuttle antibody for Alzheimer’s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 22, 149–162 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29298417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. 5, 354–363 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, K. Y., Schneider, L. S. &amp; Howard, R. The need to show minimum clinically important differences in Alzheimer’s disease trials. Lancet Psychiatry 8, 1013–1016 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34087114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klunk, W. E. et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11, 1–15.e4 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25443857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miles, L. A., Crespi, G. A., Doughty, L. &amp; Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci. Rep. 3, 1302 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23416764</ArticleId>
            <ArticleId IdType="pmc">3575012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Englund, H. et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103, 334–345 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17623042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy, J. The relationship between amyloid and tau. J. Mol. Neurosci. 20, 203–206 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12794314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lantos, P. L. et al. Familial Alzheimer’s disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer’s disease have the same cytoskeletal pathology. Neurosci. Lett. 137, 221–224 (1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1584463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanger, D. P., Mann, D. M., Neary, D. &amp; Anderton, B. H. Tau pathology in a case of familial Alzheimer’s disease with a valine to glycine mutation at position 717 in the amyloid precursor protein. Neurosci. Lett. 145, 178–180 (1992).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1465214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutton, M. et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9641683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert, M., Crowther, R. A. &amp; Spillantini, M. G. Tau mutations cause frontotemporal dementias. Neuron 21, 955–958 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9856453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak, H., Thal, D. R., Ghebremedhin, E. &amp; Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22002422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnsten, A. F. T., Datta, D., Tredici, K. D. &amp; Braak, H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement. 17, 115–124 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33075193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack, C. R. Jr. et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20083042</ArticleId>
            <ArticleId IdType="pmc">2819840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol. Med. 11, e11170 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31709776</ArticleId>
            <ArticleId IdType="pmc">6895602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34083813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho, H. et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30926651</ArticleId>
            <ArticleId IdType="pmc">6836867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack, C. R. Jr. et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain 141, 1517–1528 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29538647</ArticleId>
            <ArticleId IdType="pmc">5917767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aschenbrenner, A. J., Gordon, B. A., Benzinger, T. L. S., Morris, J. C. &amp; Hassenstab, J. J. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91, e859–e866 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30068637</ArticleId>
            <ArticleId IdType="pmc">6133625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915–924 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31157827</ArticleId>
            <ArticleId IdType="pmc">6547132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Joie, R. et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, eaau5732 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31894103</ArticleId>
            <ArticleId IdType="pmc">7035952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30326496</ArticleId>
            <ArticleId IdType="pmc">6233630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busche, M. A. &amp; Hyman, B. T. Synergy between amyloid-beta and tau in Alzheimer’s disease. Nat. Neurosci. 23, 1183–1193 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32778792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Driscoll, I. et al. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol. 124, 823–831 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22864813</ArticleId>
            <ArticleId IdType="pmc">3566238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis, C. et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72, 287–294 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25622185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabri, O. et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 11, 964–974 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25824567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 11, 669–678 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22749065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navitsky, M. et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 14, 1565–1571 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30006100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 13, 205–216 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27697430</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
